CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 782 enrolled
Drug / intervention
Evolocumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03900026
NCT03900026Phase 4Completed
CompareCT.gov

A Randomized Trial of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery (NEWTON-CABG)

Unity Health Toronto·interventional·Posted Apr 2, 2019·Updated Aug 29, 2025

In Brief

A Phase 4 clinical trial evaluating Evolocumab and Placebo for Coronary Artery Bypass Graft Surgery and 2 related conditions. Completed, enrolled 782 participants across 22 sites in 4 countries.

Detailed Summary

The purpose of this study is to determine if evolocumab added to regular statin therapy improves vein graft patency after coronary artery bypass graft (CABG) surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion
CountriesAustralia, Canada, Hungary, United States
CollaboratorsApplied Health Research Centre

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedApr 2, 2019
Enrollment StartMay 30, 2019
Primary CompletionJan 30, 2025
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 7.3 years ago

Interventions

Evolocumabdrug

REPATHA (evolocumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); it will be administered via subcutaneous injection

Placeboother

Placebo cartridges will contain vehicle only; placebo will be administered via subcutaneous injection.